ASX:BD1 BARD1 Life Sciences (BD1) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free BD1 Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume801,545 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BARD1 Life Sciences alerts: Email Address Ad Weiss RatingsNvidia Has a BIG Problem — Here’s Who Benefits MOST#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'If You Missed Out On The AI Boom, Take These 3 Steps About BARD1 Life Sciences Stock (ASX:BD1)BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.Read More Ad Weiss RatingsNvidia Has a BIG Problem — Here’s Who Benefits MOST#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'If You Missed Out On The AI Boom, Take These 3 Steps BD1 Stock News HeadlinesMarch 14, 2023 | npr.orgLife KitFebruary 12, 2023 | theguardian.comTake AstraZeneca’s warning seriously. The UK is missing out in life sciencesApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereFebruary 5, 2023 | cnet.comSee a Real-Life 'Terminator' Robot Turn Into Liquid to Bust Out of a CageJanuary 14, 2023 | bizjournals.comBay Area's biggest life science stock winners and losers in 2022January 13, 2023 | finance.yahoo.comJUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIANovember 17, 2022 | marketwatch.comSELLAS Life Sciences Group Shares Drop 40% on Clinical Trial UpdateOctober 13, 2022 | techcrunch.comQuantori is building an app development platform focused on life sciencesApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereAugust 25, 2022 | finance.yahoo.comBD Promotes Two Senior Executives to Segment Leadership RolesDecember 9, 2021 | msn.comWhy has the BARD1 (ASX:BD1) share price vanished from the ASX boards?November 12, 2021 | fool.com.auBARD1 (ASX:BD1) share price ends stellar day up 41%November 11, 2021 | msn.comBARD1 Life Sciences (ASX:BD1) share price leaps 15% on US patent newsAugust 17, 2021 | msn.comBARD1 Life Sciences (ASX:BD1) share price jumps on cancer test updateJuly 30, 2021 | msn.comHere’s why the BARD1 (ASX:BD1) share price is falling 7% todayJuly 26, 2021 | proactiveinvestors.com.hkBARD1 Life Sciences raises $15 million to accelerate cancer diagnostic test developmentJuly 23, 2021 | msn.comBARD1 (ASX:BD1) share price falls 6% on placement updateSee More Headlines Receive BD1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:BD1 CUSIPN/A CIKN/A Webwww.bard1.com Phone61 8 9381 9550FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.35 Current Ratio3.87 Quick Ratio3.58 Sales & Book Value Annual Sales$1.27 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.33 Book ValueA$0.36 per share Price / BookN/AMiscellaneous Outstanding Shares92,018,704Free FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Leearne Maree Hinch BSc.B.V.M.S., M.R.C.V.S., M.B.A., Chief Exec. OfficerMr. Peter Lynton Gunzburg B Comm (Age 69)ASIA, Managing Director Comp: $82.12kMr. Tony Di Pietro AGIAC.A., M.A.I.C.D., B.Com, CPA, CFO & Joint Company Sec.Mr. Carl S. StubbingsChief Operating OfficerDr. Peter William French M.B.A.B.Sc., M.Sc., Ph.D., MBA, FRSM, Chief Scientific OfficerMs. Pauline Anne Collinson (Age 65)Joint Company Sec. More ExecutivesKey CompetitorsANGLEOTCMKTS:ANPCYArrayitOTCMKTS:ARYCAustralian Clinical LabsASX:ACLBCAL DiagnosticsASX:BDXbioAffinity TechnologiesNASDAQ:BIAFWView All Competitors This page (ASX:BD1) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe Next Nvidia?InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BARD1 Life Sciences Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.